Executive Vice President Jeff Lamb said Monday that the changes would "help support the transformation of our brand in this tough industry."
ALSO ONLINE: Southwest Airlines begins enforcing 'no-show' policy
VIDEO: Travel Q&A: Is Southwest Airlines right for you?
The airline named Andrew Watterson as vice president of network planning and performance. He had been vice president of planning and revenue management at Hawaiian Airlines.
Sherry Staber, a vice president at department store chain J.C. Penney, was named vice president of business transformation in the airline's technology organization.
A Southwest spokeswoman said that Staber took over the duties of one or two vacant positions and that Watterson did not replace anyone.
Top Growth Companies To Buy Right Now: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
Advisors' Opinion:- [By John Udovich]
Biotech stocks and especially anything related to cancer has been a hot sector this year with plenty of good news with small cap cancer stocks like Clovis Oncology Inc (NASDAQ: CLVS), Celldex Therapeutics, Inc.(NASDAQ: CLDX) and MetaStat Inc (OTCBB: MTST). also recently reporting their share of good news. I should point out that one reason biotech or rather cancer is a hot area right now is because�big pharma companies who are loosing their�patent protection are looking for acquisitions with cancer in particular being a hot area. In addition and�thanks to a series of breakthroughs that have helped researchers understand the genetic basis of the disease, more investment or R&D dollars are flowing into cancer therapies or small cap biotechs in the cancer space.�With that in mind, here is the latest news about cancer or the cancer stocks or drug companies involved with finding new cancer treatments:
- [By James E. Brumley]
Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.
- [By Jake L'Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By Keith Speights]
Give me a double
The Motley Fool's David Williamson summed up the great week for Clovis Oncology (NASDAQ: CLVS ) perfectly in his headline a few days ago: "1 Biotech + 2 Cancer Drugs = 100% Pop." While that 100% pop drifted down to 96% by the end of the week, Dave hit the nail on the head.
Hot Tech Stocks To Invest In Right Now: Foundation Medicine Inc (FMI)
Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.
FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.
Advisors' Opinion:- [By James E. Brumley]
It wouldn't be fair to say there's nothing like it "out there", because there is. A company called Foundation Medicine Inc. (NASDAQ:FMI) has developed a similar/comparable app. The CLRX version of the solution appears superior in most ways, however, if for no other reason than because of the projected revenue growth the company is apt to see.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By RedChip]
According to Walter Isaacson�� biography, Steve Jobs paid a reported $100,000 to learn the DNA sequence of his cancer. This work, completed at MIT and Harvard, led to the launch of Foundation Medicine (NASDAQ: FMI). Foundation Medicine has grabbed headlines over the past couple of weeks as it entered the capital markets with a high-profile IPO led by Goldman Sachs.
- [By Dan Caplinger]
In the following video, Dan Caplinger, director of investment planning for The Motley Fool, looks at whether the IPO market is overheating once more. Dan points to some huge gains from recent IPOs, with FireEye (NASDAQ: FEYE ) rising 80% in its first day while Rocket Fuel (NASDAQ: FUEL ) and Foundation Medicine (NASDAQ: FMI ) both posted gains of between 90% and 100%. Dan also highlights Sprouts Farmers Market� (NASDAQ: SFM ) , which climbed a whopping 123% in its first day as a public company.
Hot Tech Stocks To Invest In Right Now: Makism 3D Corp (MDDD)
Makism 3D Corp., incorporated on May 4 2010, is a three dimensional (3D) printer manufacturing company. The Company produces consumer and professional grade 3D printers. The Company�� flagship product, branded as the Wideboy family of printers, offers packaging designed to fit any office or professional space.
Its 3D printers utilize British and German engineered components. Its printers are assembled in Cambridge (United Kingdom).
Advisors' Opinion:- [By John Udovich]
Small cap OTC stocks Sovereign Lithium Inc (OTCMKTS: SLCO), Life Stem Genetics Inc (OTCMKTS: LIFS), Nevada Gold Corp (OTCMKTS: NVGC), Guar Global Ltd (OTCMKTS: GGBL) and Makism 3D Corp (OTCMKTS: MDDD) all saw their trading halted late last year by the SEC, but now all of these stocks are trading again. So what's going on and why the sudden crackdown? First, here is a quick look at what happened to the following five small cap stocks:
Hot Tech Stocks To Invest In Right Now: Rosetta Genomics Ltd (ROSG)
Rosetta Genomics Ltd., incorporated on March 9, 2000, is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In July 2011, the Company launched its fifth product - miRview lung. As of December 31, 2011, the Company launched five tests based on its five microRNA technologies: miRview mets; miRview mets2; miRview squamous; miRview meso, and miRview lung.
Rimonim Consortium
In January 2011, the Company joined the Rimonim Consortium, which is supported by the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of the State of Israel, or the OCS. The purpose of the consortium is to develop RNA interference, or RNAi, -based therapeutics.
Rosetta Green
Rosetta Green Ltd. is an Israeli subsidiary of the Company, which was established to leverage its capabilities into the areas of cleantech and plant biotech by using its microRNA technologies to develop plants and algae more suitable for various applications, such as feedstocks for biofuels and agriculture. Research at the Rosetta Green project has been shown to develop algal strains with oil content, to discover potential novel microRNAs from commercially-important algae and to identify drought-regulated microRNAs in plants.
The Company competes with Pathwork Diagnostics, Inc., Biotheranostics, Inc., Combimatrix Corporation, Alnylam Pharmaceuticals, Inc., Asuragen Inc., Exiqon A/S, Life Technologies Corporation, Isis Pharmaceuticals, Merck & Co., Inc., Santaris Pharma A/S, and Regulus Therapeutics.
Advisors' Opinion:- [By John Udovich]
Small cap cancer diagnostic stock�Myriad Genetics, Inc (NASDAQ: MYGN) jumped to a five year high on Wednesday�thanks to good�news that the�government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should also mention that Myriad Genetics has been in our SmallCap Network Elite Opportunity (SCN EO) portfolio since early February and we are now up some 32.5% since then ��thanks in part to the shorts being put in a short squeeze.
- [By John Udovich]
Small cap genomics stocks Rosetta Genomics Ltd (NASDAQ: ROSG), Genomic Health, Inc (NASDAQ: GHDX) and CollabRx Inc (NASDAQ: CLRX) are at the forefront of genomics testing�or research. I should mention that Wikipedia defines genomics�as a�discipline in genetics that applies recombinant DNA, DNA sequencing methods and bioinformatics to sequence, assemble and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). A 2013 Booz Allen Hamilton report on the sector noted that in�2011, the US genetic and genomic clinical testing market size was estimated to be $5.9 billion while the�number of available tests has grown substantially from 1,680 just 4 years ago to 2,886 in 2012.
Hot Tech Stocks To Invest In Right Now: GigOptix Inc (GIG)
GigOptix, Inc. (GigOptix), incorporated on March 2008, is a supplier of semiconductor and electro-optical component products that enables high-speed end to end data streaming over optical fiber and wireless telecommunications and data-communications networks globally. The Company's products convert signals between electrical and optical formats for transmitting and receiving data over fiber optic networks and between electrical and high speed radio frequencies to enable the transmission and receipt of data over wireless networks. The Company is creating both optical telecommunications and data-communications applications for fast growing markets in 10 giga bytes per second (Gbps), 40Gbps and 100Gbps drivers, receiver integrated circuits (IC), electro-optic modulator components and multi-chip-modules (MCM), as well as E-band wireless data-communications applications for high speed mobile backhaul and other high capacity wireless data transport applications. During the year ended December 31, 2011, the Company shipped over 150 products to over 200 customers.
The Company offers a portfolio of 10Gbps and 40Gbps electro-optical products and is developing market for 100Gbps products. The Company provides bundled solutions that consist of a few of its products, such as modulator and driver. The Company also offers a comprehensive portfolio of Monolithic Microwave Integrated Circuit (MMIC) and application-specific integrated circuit (ASIC) products to support E-band wireless communication and defense markets. The Company has also developed 10Gbps vertical cavity surface-emitting laser (VCSEL) drivers and receivers for aerospace as well as outdoor, non-temperature controlled environments that enables higher capacity in its customers' next generation flight and data center systems.
The Company has a portfolio of products for telecommunications , data-communications, defenses and industrial applications designed for optical speeds from 3Gbps to over 100Gbps and for wireless frequencies! from zero giga hertz (GHz) to 86GHz. The Company's products support a range of data rates, protocols, transmission distances and industry standards.
The Company's portfolio consists of the product ranges, such as laser and modulator drivers for 10Gbps, 40Gbps and 100Gbps applications; receiver amplifiers or Trans-impedance Amplifiers (TIAs) for 10Gbps, 40Gbps and 100Gbps applications; VCSEL driver and receiver chipsets for 14 and 12 channel parallel optics applications from 3Gbps to 10Gbps; Electro-optic modulators based on the Company's TFPS technology suitable for various 40Gbps and 100Gbps modulation schemes, such as differential phase shift keying (DPSK), differential quadrature phase shift keying (DQPSK), RZ-DQPSK and DP-QPSK; wideband monolithic microwave integrated circuit (MMIC) amplifiers with flat gain response; high frequency MMIC Power Amplifiers with high gain and output power; high frequency passive attenuators and filters in small form factors, and standard cell, and structured ASIC and hybrid ASIC designs and manufacturing service for multiple markets offering information technology acquisition review (ITAR) compliance for defense applications. The Company designs and market products that amplifies electrical signals during both the transmission (amplifiers and optical drivers) and reception (TIAs) of optical signals as well as modulate optical signals in the transmission of data.
The Company's optical drivers amplify the input digital data stream that is used to modulate laser light either by direct modulation of the laser or by use of an external modulator that acts as a precise shutter to switch on and off light to create the optical data stream. The Company supplies an optimized component for each type of laser, modulator and photo-diode depending upon the speed, reach and required cost. The Company's microwave and millimeter wave amplifiers amplify small signal radio signals into more signals that can be transmitted over long distances to establish high t! hroughput! data connections or enable radar based applications. The Company's ASIC solutions are used in a number of applications such as defense and test and measurement applications to enable the high speed processing of complex signals.
The Company's product portfolio is designed to cover the range of solutions needed in these different modules. The Company's product portfolio consists of five product lines: GX Series, which includes serial drivers and TIA ICs devices for telecom and data-com markets; HX Series, which includes multi-channel driver and TIA ICs for short reach data-com and optical interconnect applications; LX Series, which includes TFPS modulators for high speed telecom and defense applications; EX Series, which includes amplifiers, filters and attenuators for microwave applications in defense and instrumentation, and CX Series, which includes family of ASIC solutions for custom integrated circuit design.
GX Series
The GigOptix GX Series of products services both the telecom and data-com markets with a broad portfolio of drivers and transimpedence amplifiers that address 10Gbps, 40Gbps and 100Gbps speeds over distances that range from 100 meters to 10,000 kilometers. The GX Series devices are used in FiberChannel, Ethernet, synchronous optical networking (SONET)/ synchronous digital hierarchy (SDH) components and those based upon the optical internetworking forum (OIF) standards.
HX Series
The GigOptix HX Series of products service the high performance computing (HPC), data-com and consumer markets with a portfolio of parallel VCSEL drivers and TIAs that address 3Gbps, 5Gbps,10Gbps, 14Gbps, 16Gbps and 25Gbps channel speeds over 100-300 meters distances in four and 12 channel configurations. The HX Series devices are used in HPC formats, Infiniband, Ethernet and optical high definition multimedia interface (HDMI) components.
LX Series
The GigOptix LX Series of products service the 40Gbps and above telecom! market f! or Mach-Zehnder modulators. The LX Series devices are based on the Company's TFPS EO material technology.
EX Series
The GigOptix EX Series of products leverages the high performance products acquired in the Endwave acquisition. In addition, it also includes the die and design techniques developed for the GX Series telecom and data-com drivers for related defense and instrumentation applications.
CX Series
The GigOptix CX Series of products offers a portfolio of distinct paths to digital and analog mixed signal ASICs with the capability of supporting designs of up to 10M gates in technologies ranging from 0.6 through 65nm. The CX Series uses the Company's technology in Structured and Hybrid ASICs to enable a generic ASIC solution that can be customized for a customer using only a few metal mask layers. The CX Series also offers ASIC services, including Analog and Mixed Signal IP into designs and taking customers designs from RTL or gate-level net list definitions to volume production with third party foundries.
The Company competes with TriQuint, Rohm, InPhi, Centellax, Semtech, Vitesse, M/A-Com, Avago, Emcore, Tyco Electronics, IPtronics. Avago, Emcore, Tyco Electronics, JDSU, Oclaro, Sumitomo, Fujitsu, Emcore, Oclaro, Hittite, Sumitomo, Hittite, RFMD, Northrop Grumman, On -Semiconductor, eSilicon, Open Silicon, Faraday, Toshiba and eASIC.
Advisors' Opinion:- [By maarnio]
Lightwave Logic�� main competitor is GigOptix (GIG). GigOptix has designed and patented potentially commercially feasible electro-optic polymers and holds an exclusive license to all electro-optic polymeric technology developed at the University of Washington.
- [By Bryan Murphy]
It's admittedly overbought and due for a slight dip thanks to today's surge. But when you take a step back and look at GigOptix Inc. (NYSEMKT:GIG), there's actually a lot to be excited about if you've been mulling a trading in GIG. The trick will be getting the timing right.
Hot Tech Stocks To Invest In Right Now: Lam Research Corporation(LRCX)
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipments used in the fabrication of integrated circuits. The company offers etch products that remove portions of various films from the wafer in the creation of semiconductor devices. Its etch products include dielectric etch, conductor etch, three-dimensional integrated circuit etch, MEMS devices, CMOS image sensors, and power devices for etching process. Lam Research Corporation also provides wafer cleaning steps that comprise post-etch and post-strip cleans, and pre-diffusion and pre-deposition cleans; and single-wafer wet clean and plasma-based bevel clean systems. The company offers its products to semiconductor manufacturers. It operates in the United States, Europe, Taiwan, Korea, Japan, and the Asia Pacific. Lam Research Corporation was founded in 1980 and is headquartered in Fremont, California.
Advisors' Opinion:- [By Sue Chang and Saumya Vaishampayan]
$KLAC: KLA-Tencor Corp. (KLAC) �shares rose 1.9%. Analysts at J.P. Morgan on Monday initiated coverage of KLA-Tencor and Lam Research Corp. (LRCX) �at overweight.
- [By Sam Collins]
Lam Research (LRCX) — This is one of the leading manufacturers of etch products, used to etch away portions of films to create integrated circuits (IC).
- [By Ben Axler]
In addition, the company announced in December 2012 that it entered a strategic collaboration agreement on ion implant, dry-strip, etch processes, and photoresist strip applications, including material modification implants and high-dose implant strip (HDIS) with Lam Research (LRCX). Lam also agreed to acquire ACLS's dry strip intellectual property and technology for $10.7m ($8.7m received immediately, and $2.0m based on milestones). ACLS will indefinitely retain the entire service and support contracts of its dry strip installed base. In addition to the immediate financial benefits, ACLS benefits from a partnership with Lam by getting better visibility into end customer problems, and the ability to expand addressable market opportunities.
No comments:
Post a Comment